The anti-tumor effect of dinaciclib is likely mediated through cell cycle inhibition and apoptosis induction given that CKD1, cyclin B1, Aurora A, Mcl-1, Bcl-xL, survivin and pro-caspase-3 levels were all decreased. The gene discussed is BIRC5; the disease is neoplasm.